Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has received an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $48.50.

Several brokerages recently commented on AAPG. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a report on Monday, November 24th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Piper Sandler began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Finally, BTIG Research began coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target for the company.

Ascentage Pharma Group International Trading Down 0.7%

Shares of NASDAQ AAPG opened at $27.68 on Friday. The stock’s 50 day moving average price is $31.64 and its two-hundred day moving average price is $36.68. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a 52-week low of $16.50 and a 52-week high of $48.45.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $204,000. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter valued at about $227,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Finally, Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the second quarter valued at about $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.